NEW YORK (GenomeWeb) – Exosome Diagnostics announced last week the launch of a clinical commercialization program to help researchers bring exosome-based biosignature assays to the clinical lab.

Through the free program, called "Academic Bench to Clinical Diagnostics," or A to D, Exosome will help researchers port existing assays to the firm's patented exosome isolation and nucleic acid extraction system to increase sensitivity, and then guide the test through the regulatory and reimbursement process.